Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon...

IgA Nephropathy Takes Center Stage with Various Patient and Payer Events in July NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to raise awareness of both the unique challenges faced by people living with IgA nephropathy and of the resources and...

Calliditas Therapeutics Launches an Online Patient Platform STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online...